I am/have/had
I am looking for
Advanced Filters
Found 245 clinical trials
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …
cancer therapy
neuropathy
dexamethasone
ejection fraction
recurrent disease
- 0 views
- 04 Dec, 2020
- 5 locations